Restricted accessResearch articleFirst published online 2022-12
Effects of different routes of administration and doses of Sulodexide on leukocyte-endothelium interaction and tissue perfusion on an animal model of low flow and high pressure in veins
To assess the effects of different doses and routes of Sulodexide on leukocyte-endothelium interaction and tissue perfusion in a model of venous hypertension and low blood flow.
Methods
Six weeks after venous hypertension induction, through external iliac vein ligature male hamsters (Mesocricetus auratus) received Sulodexide at 1, 2, or 4 mg/kg/day or saline (placebo) by subcutaneous or intramuscular routes during 2 or 4 weeks. After treatments, leukocyte rolling and adhesion, functional capillary density (FCD), and venular diameter were evaluated on the affected hindlimb.
Results
Subcutaneous and intramuscular treatments with Sulodexide after 2 and 4 weeks, significantly reduced leukocyte rolling and adhesion and increased FCD. Sulodexide did not affect venular diameter and intramuscular treatment was more effective in reducing leukocyte adhesion than the subcutaneous one.
Conclusion
This preliminary study demonstrated that Sulodexide significantly decreased leukocyte-endothelium interaction and improved tissue perfusion in hamsters subjected to venous hypertension and low blood flow.
HamdanA. Management of varicose veins and venous insufficiency. JAMA2012; 308: 2612–2621.
2.
MannelloFLigiDCanaleM, et al.Sulodexide down-regulates the release of cytokines, chemokines, and leukocyte colony stimulating factors from human macrophages: role of glycosaminoglycans in inflammatory pathways of chronic venous disease. Curr Vasc Pharmacol2014; 12: 173–185.
3.
RaffettoJD. Dermal pathology, cellular biology and inflammation in chronic venous disease. Thromb Res2009; 123: S66–S71.
4.
ChatterjeeSFisherAB. Mechanotransduction in the endothelium: role of membrane proteins and reactive oxygen species in sensing, transduction, and transmission of the signal with altered blood flow. Antioxid Redox Signal2014; 20: 899–913.
5.
ChatterjeeS. Endothelial mechanotransduction, redox signaling and the regulation of vascular inflammatory pathways. Front Physiol2018; 9: 1–16.
6.
AndreozziGM. Role of sulodexide in the treatment of CVD. Int Angiol2014; 33: 255–262.
7.
MooreKHMurphyHAGeorgeEM, et al.The glycocalyx: a central regulator of vascular function. Am J Physiol Regul Integr Comp Physiol2021; 320: R508–R518.
8.
CarrollBJPiazzaGGoldhaberSZ, et al.Sulodexide in venous disease. J Thromb Haemost2019; 17: 31–38.
9.
Castro-FerreiraRCardosoRLeite-MoreiraA, et al.The role of endothelial dysfunction and inflammation in chronic venous disease. Ann Vasc Surg2018; 46: 380–393.
10.
CoccheriSMannelloF. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Devel Ther2013; 8: 49–65.
11.
BignaminiAAMatuškaJ. Sulodexide for the symptoms and signs of chronic venous disease: a systematic review and meta-analysis. Adv Ther2020; 37: 1013–1033.
12.
PompilioGNicolaidesAKakkosSK, et al.Systematic literature review and network Meta-analysis of sulodexide and other drugs in chronic venous disease. Phlebology2021; 36: 695–709.
13.
Lasierra-CirujedaJCoronelPAzaM, et al.Use of sulodexide in patients with peripheral vascular disease. J Blood Med2010; 1: 105–115.
14.
SouzaMGCCyrinoFZGACarvalhoJJ, et al.Protective effects of micronized purified flavonoid fraction (MPFF) on a novel experimental model of chronic venous hypertension. Eur J Vasc Endovasc Surg2018; 55: 694–702.
15.
Research Council National. Guide for the Care and Use of Laboratory Animals. Washington, DC: The National Academies Press, 2011.
16.
SimõesCSvensjöEBouskelaE, et al.Effects of L-NA and sodium nitroprusside on ischemia/reperfusion-induced leukocyte adhesion and macromolecular leakage in hamster cheek pouch venules. Microvasc Res2001; 62: 128–135.
17.
ReitsmaSSlaafDWVinkH, et al.The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch2007; 454: 345–359.
18.
van den BergBMSpaanJARolfTM, et al.Atherogenic region and diet diminish glycocalyx dimension and increase intima-to-media ratios at murine carotid artery bifurcation. Am J Physiol Heart Circ Physiol2006; 290: H915–H920.
19.
GouverneurMSpaanJAPannekoekH, et al.Fluid shear stress stimulates incorporation of hyaluronan into endothelial cell glycocalyx. Am J Physiol Heart Circ Physiol2006; 290: H458.
20.
YangHZhuLChaoY, et al.Hyaluronidase2 (Hyal2) modulates low shear stress-induced glycocalyx impairment via the LKB1/AMPK/NADPH oxidase-dependent pathway. J Cell Physiol2018; 233: 9701–9715.
21.
VinkHDulingBR. Identification of distinct luminal domains for macromolecules, erythrocytes, and leukocytes within mammalian capillaries. Circ Res1996; 79: 581–589.
22.
NieuwdorpMMeuweseMCMooijHL, et al.Measuring endothelial glycocalyx dimensions in humans: a potential novel tool to monitor vascular vulnerability. J Appl Physiol2008; 104: 845–852.
23.
BrandsJvan HaareJVinkH, et al.Whole-body recruitment of glycocalyx volume during intravenous adenosine infusion. Physiol Rep2013; 1: e00102.
24.
HenryCBDulingBR. TNF-a increases entry of macromolecules into luminal endothelial cell glycocalyx. Am J Physiol2000; 279: H2815–H2823.
25.
PlattsSHLindenJDulingBR, et al.Rapid modification of the glycocalyx caused by ischemia-reperfusion in inhibited by adenosine A2A receptor activation. Am J Physiol2003; 284: H2360–H2367.
26.
MulivorAWLipowskyHH. Inflammation- and ischemia induced shedding of venular glycocalyx. Am J Physiol2004; 286: H1672–H1680.
27.
BroekhuizenLNLemkesBAMooijHL, et al.Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia2010; 53: 2646–2655.
28.
MannelloFRaffettoJD. Matrix metalloproteinase activity and glycosaminoglycans in chronic venous disease: the linkage among cell biology, pathology and translational research. Am J Transl Res2011; 3: 149–158.
29.
LigiDMostiGCroceL, et al.Chronic venous disease – part II: proteolytic biomarkers in wound healing. Biochim Biophys Acta2016; 1862: 1900–1908.
30.
GrangerDNKubesP. The microcirculation and inflammation: modulation of leukocyte-endothelial cell adhesion. J Leukoc Biol1994; 55: 662–675.
31.
CheatleTRSarinSSmithPDC, et al.The pathogenesis of skin damage in venous disease: a Review. Eur J Vasc Surg1991; 5: 115–123.
32.
BurnandKGWhimsterINaidooA, et al.Pericapillary fibrin in the ulcer-bearing skin of the leg: the cause of lipodermatosclerosis and venous ulceration. Br Med J1982; 285: 1071–1072.
33.
BerganJJSchmid-SchonbeinGWColeridge SmithPD, et al.Chronic venous disease. N Engl J Med2006; 355: 488–498.
34.
JüngerMSteinsAHahnM, et al.Microcirculatory dysfunction in chronic venous insufficiency (CVI). Microcirculation2000; 7: S3–S12.
35.
BarbantiMGuizzardiSCalanniF, et al.Antithrombotic and thrombolytic activity of sulodexide in rats. Int J Clin Lab Res1992; 22: 179–184.
36.
MauroMFerraroGPalmieriGC. Profibrinolytic and antithrombotic effects of sulodexide oral administration: a double-blind, cross-over, placebo-controlled study. Curr Ther Res1992; 51: 342–350.
37.
CerlettiCRajtarGMarchiE. Interaction between glycosaminoglycans, platelets, and leukocytes. Semin Thromb Hemost1994; 20: 245–253.
38.
Badier-CommanderCVerbeurenTLebardC, et al.Increased TIMP/MMP ratio in varicose veins: a possible explanation for extracellular matrix accumulation. J Pathol2000; 192: 105–112.
39.
Sansilvestri-MorelPNonotteIFournet-BourguignonMP, et al.Abnormal deposition of extracellular matrix proteins by cultured smooth muscle cells from human varicose veins. J Vasc Res1998; 35: 115–123.
40.
Sansilvestri-MorelPRupinAJaissonS, et al.Synthesis of collagen is dysregulated in cultured fibroblasts derived from skin of subjects with varicose veins as it is in venous smooth muscle cells. Circulation2002; 106: 479–483.
41.
LowellRCGloviczkiPMillerVM, et al.In vitro evaluation of endothelial and smooth muscle function of primary varicose veins. J Vasc Surg1992; 16: 679–686.
42.
RaffettoJDYuWWangX, et al.Sulodexide Improves Contraction and Decreases Matrix Metalloproteinase-2 and -9 in Veins Under Prolonged Stretch. J Cardiovasc Pharmacol2020; 75: 211–221.
43.
SavianoMMaletiOLiguoriL, et al.Double-blind, double-dummy, randomized, multi-centre clinical assessment of the efficacy, tolerability and dose-effect relationship of sulodexide in chronic venous insufficiency. Curr Med Res Opin1993; 13: 96–108.
44.
MartignoniMGroothuisGMde KanterR, et al.Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol2006; 2: 875–894.
45.
LowLAMummeryCBerridgeBR, et al.Organs-on-chips: into the next decade. Nat Rev Drug Discov2021; 20: 345–361.
